Loading...
Loading...
According to a research report published earlier today, Wedbush has increased NuPathe Inc.'s
PATH PT from $17 to $18.
In the report, Wedbush commented, “We see PATH potentially doubling or more in 2012 and reiterate our Outperform rating and are increasing our fair value to $18 for time value. With potential approval by year-end 2012 and PATH having a lead asset which could reach peak sales of $300 million or more, we believe the stock is an attractive buying opportunity. We calculate PATH's fair value based on a 30% annual discount and a 1x-10x premium range on our net peak annual sales estimate for each product and indication in the clinic to reflect risk.”
NuPathe is currently trading at $4.13.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in